Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
clinical trials
life sciences
national blog main
new york blog main
san francisco blog main
boston blog main
boston top stories
national top stories
new york top stories
rare disease drugs
san francisco top stories
acute migrane
acute myeloid leukemia
alx oncology
astellas pharma
atlas venture
audentes therapeutics
autoimmune diseases
avidity biosciences
bain capital
bausch health
berkeley lights
biotech ipos
bluebird bio
boston
breast cancer
cancer drugs
cancer immunotherapy
cd47
chronic kidney disease
deals
deerfield healthcare technology acquisitions
deerfield management company
desmoid tumor
dihydroergotamine
dihydroergotamine mesylate
duchenne muscular dystrophy
dyne therapeutics
europe blog main
What
ipo
3
×
ipos
3
×
biotech
companies
days
drug
hasn’t
slowed
activity
ago
arrival
biotechs
considering
data
diseases
dog
dyne
early
expected
experimental
eyes
firm
genetic
having
humans
industry
leading
life
line
long
market
medicines
migraine
momentum
muscle
new
pfizer
place
prep
raised
Language
unset
3
×
Current search:
ipo
×
ipos
×
unset
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs